NVAX is one, of all the COVID-2019 movers, that we think is most likely to end up being a great short down the line.
The long-term trajectory speaks of numerous failures to execute in clinical development, and the company is not part of the inside clique with funding to solve the virus vaccine puzzle. But it's up almost 100% since the news first broke last month.